Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Costs of continuing RTS,S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries.
Baral R, Levin A, Odero C, Pecenka C, Tabu C, Mwendo E, Bonsu G, Bawa J, Dadzie JF, Charo J, Antwi-Agyei KO, Amponsa-Achianou K, Jalango RE, Mkisi R, Gordon S, Mzengeza T, Morgan W, Muhib F. Baral R, et al. Among authors: charo j. PLoS One. 2021 Jan 11;16(1):e0244995. doi: 10.1371/journal.pone.0244995. eCollection 2021. PLoS One. 2021. PMID: 33428635 Free PMC article.
Correction: Costs of continuing RTS,S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries.
Baral R, Levin A, Odero C, Pecenka C, Tabu C, Mwendo E, Bonsu G, Bawa J, Dadzie JF, Charo J, Antwi-Agyei KO, Amponsa-Achianou K, Jalango RE, Mkisi R, Gordon S, Mzengeza T, Morgan W, Muhib F. Baral R, et al. Among authors: charo j. PLoS One. 2021 Apr 22;16(4):e0250863. doi: 10.1371/journal.pone.0250863. eCollection 2021. PLoS One. 2021. PMID: 33886689 Free PMC article.
Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer.
Prenen H, Deva S, Keam B, Lindsay CR, Lugowska I, Yang JC, Longo F, de Miguel M, Ponz-Sarvise M, Ahn MJ, Gumus M, Champiat S, Italiano A, Salas S, Perets R, Arslan C, Cho BC, Evers S, Boetsch C, Marbach D, Dejardin D, Sleiman N, Ardeshir C, Richard M, Charo J, Kraxner A, Keshelava N, Teichgräber V, Moreno V. Prenen H, et al. Among authors: charo j. Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-23-2677. Online ahead of print. Clin Cancer Res. 2024. PMID: 38709220
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.
Steeghs N, Gomez-Roca C, Rohrberg KS, Mau-Sørensen M, Robbrecht D, Tabernero J, Ahmed S, Rodriguez-Ruiz ME, Ardeshir C, Schmid D, Sleiman N, Watson C, Piper-Lepoutre H, Dejardin D, Evers S, Boetsch C, Charo J, Teichgräber V, Melero I. Steeghs N, et al. Among authors: charo j. Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-3567. Online ahead of print. Clin Cancer Res. 2024. PMID: 38630781
Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies.
Dziadek S, Kraxner A, Cheng WY, Ou Yang TH, Flores M, Theiss N, Tsao TS, Andersson E, Harring SV, Bröske AE, Ceppi M, Teichgräber V, Charo J. Dziadek S, et al. Among authors: charo j. Front Immunol. 2024 Mar 15;15:1352615. doi: 10.3389/fimmu.2024.1352615. eCollection 2024. Front Immunol. 2024. PMID: 38558814 Free PMC article.
Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
Deycmar S, Johnson BJ, Ray K, Schaaf GW, Ryan DP, Cullin C, Dozier BL, Ferguson B, Bimber BN, Olson JD, Caudell DL, Whitlow CT, Solingapuram Sai KK, Romero EC, Villinger FJ, Burgos AG, Ainsworth HC, Miller LD, Hawkins GA, Chou JW, Gomes B, Hettich M, Ceppi M, Charo J, Cline JM. Deycmar S, et al. Among authors: charo j. J Transl Med. 2024 Mar 19;22(1):292. doi: 10.1186/s12967-024-04869-6. J Transl Med. 2024. PMID: 38504345 Free PMC article.
Systemic Immune Response to a CD40-Agonist Antibody in Nonhuman Primates.
Caudell DL, Dugan GO, Babitzki G, Schubert C, Braendli-Baiocco A, Wasserman K, Acona G, Stern M, Passioukov A, Cline JM, Charo J. Caudell DL, et al. Among authors: charo j. J Leukoc Biol. 2024 Feb 19:qiae031. doi: 10.1093/jleuko/qiae031. Online ahead of print. J Leukoc Biol. 2024. PMID: 38372596
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
Peters S, Angevin E, Alonso-Gordoa T, Rohrberg K, Melero I, Mellado B, Perez-Gracia JL, Tabernero J, Adessi C, Boetsch C, Watson C, Dal Porto J, Dejardin D, Del Nagro C, Nicolini V, Evers S, Klein C, Leutgeb B, Pisa P, Rossmann E, Saro J, Umana P, Charo J, Teichgräber V, Steeghs N. Peters S, et al. Among authors: charo j. Clin Cancer Res. 2024 Apr 15;30(8):1630-1641. doi: 10.1158/1078-0432.CCR-23-2658. Clin Cancer Res. 2024. PMID: 38319672
52 results